Who Owns LifeMD Company?

Who Owns LifeMD?

Understanding the ownership structure of a company like LifeMD is crucial for discerning its strategic direction, accountability, and overall influence within the rapidly evolving telehealth industry. A pivotal event in LifeMD's trajectory, the company's continuous focus on expanding its virtual healthcare services and strategic acquisitions, underscores the dynamic nature of its ownership and its impact on market positioning.

LifeMD, Inc., originally known as Conversion Labs, Inc., was founded in 1994 and is headquartered in New York. Its vision centers on providing accessible, convenient, and cost-effective virtual healthcare services across various therapeutic areas. As of July 18, 2025, LifeMD boasts a market capitalization of approximately $0.48 billion, reflecting its significant presence in the digital health sector. The company operates as a multi-specialty telehealth provider, connecting patients with licensed healthcare professionals for online consultations, diagnoses, and prescription fulfillment. It employs a direct-to-consumer model, leveraging technology to streamline access to medical care and treatment plans for common conditions, with reported consolidated revenue of $212.5 million in 2024, representing a 39.27% increase from the previous year. LifeMD projects its 2025 revenue to be in the range of $265 million to $275 million, with telehealth revenue specifically projected between $205 million and $213 million.

Delving into the intricacies of LifeMD ownership reveals a landscape shaped by institutional investors, executive leadership, and potentially significant individual stakes. As a publicly traded entity, LifeMD stock ownership is distributed among various entities, each with a vested interest in the company's performance and strategic decisions. Examining the LifeMD company structure provides insight into who controls LifeMD stock and the broader LifeMD investor relations landscape. Understanding the LifeMD company history ownership and acquisition history is key to appreciating its current stakeholder composition.

The question of; Who owns LifeMD; is multifaceted, encompassing both the LifeMD parent company's public trading status and the specific entities holding substantial portions of its shares. The LifeMD board of directors plays a critical role in governance, often reflecting the interests of major shareholders. Furthermore, insights into LifeMD executive leadership ownership can illuminate the alignment between management and shareholder value. The LifeMD company legal ownership structure and any potential LifeMD private equity ownership are also important considerations for a comprehensive understanding.

To fully grasp the ownership dynamics, one must consider the LifeMD founder ownership stake and how it has evolved since the company's inception. Analyzing the LifeMD company ownership breakdown, including the percentage of LifeMD owned by its founders, offers a historical perspective. The presence of LifeMD institutional investors is a significant factor in its market valuation and strategic direction. Understanding who are the largest shareholders of LifeMD is paramount for anyone seeking to comprehend the company's governance and future trajectory, including its LifeMD BCG Matrix.

LifeMD, Inc., originally established as Conversion Labs, Inc. in 1994, has a foundational ownership structure significantly influenced by its co-founders. Justin Schreiber has played a pivotal role, serving as CEO and Chairman of the board of directors since 2018. Stefan Galluppi is also recognized as a co-founder. While precise initial equity distributions are not publicly detailed, as of March 2024, Justin Schreiber, Stefan Galluppi, and the broader management and founder group collectively held approximately 25% of the company. This substantial insider ownership highlights a commitment to a co-investment approach, aligning the interests of the company's leadership with those of its other investors.

The early stages of LifeMD's ownership involved initial funding rounds, with the first recorded instance occurring on August 9, 2017. ApolloMed is identified as an institutional investor that has supported the company. The company's trajectory has also involved what is described as 'consistent vettings' from institutional investors, legal firms, and auditors, particularly following periods of rapid growth. This suggests that sophisticated entities were involved in evaluating and investing in the company from its earlier phases. There is no public information available regarding early ownership disputes, buyouts, or specific agreements like vesting schedules or buy-sell clauses, but the strong founder and management ownership indicates a strategic focus on long-term value creation.

Founding Year

LifeMD was founded in 1994, initially operating under the name Conversion Labs, Inc.

Key Co-Founders

Justin Schreiber, serving as CEO and Chairman since 2018, and Stefan Galluppi are identified as co-founders.

Founder Ownership Stake

As of March 2024, founders and management collectively owned approximately 25% of the company.

First Funding Round

The company's first recorded funding round took place on August 9, 2017.

Institutional Investor Example

ApolloMed is noted as an institutional investor in LifeMD.

Early Scrutiny

The company experienced 'consistent vettings' from sophisticated entities following rapid growth.

The ownership structure of LifeMD indicates a significant alignment between its leadership and its investor base, a common characteristic in companies focusing on sustained growth and value. This approach, where founders and executives maintain a substantial stake, often reflects a deep commitment to the company's long-term vision and operational success. Understanding this foundational ownership is key to grasping the company's strategic direction and its approach to governance. For more on the company's guiding principles, you can explore its Mission, Vision & Core Values of LifeMD.

LifeMD Ownership Overview

LifeMD's ownership is characterized by a strong presence of its founders and management team, alongside institutional investment.

• Founded in 1994 as Conversion Labs, Inc.
• Co-founders include Justin Schreiber (CEO and Chairman) and Stefan Galluppi.
• Founders and management held approximately 25% of the company as of March 2024.
• ApolloMed is an identified institutional investor.
• The company has undergone scrutiny from institutional investors and other professional entities.

Complete LifeMD Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

LifeMD, Inc. has evolved into a publicly traded entity on the Nasdaq Global Market, trading under the ticker symbol LFMD. This transition marked a significant shift in its ownership structure, moving from a private entity to one with a broad base of public and institutional investors. The company's market capitalization has experienced substantial growth, increasing from less than $10 million when Justin Schreiber assumed the role of interim CEO in February 2018, to over $300 million by March 2024. By July 15, 2025, its market capitalization reached approximately $497 million, with 45.4 million shares outstanding.

The number of outstanding shares saw an increase of 17.81% over the preceding year, reaching 45.45 million as of July 2025. This growth reflects increased investor confidence and the company's expanding operations. The company's journey from a smaller enterprise to a publicly recognized entity highlights key events that have shaped its ownership landscape.

Institutional investors play a pivotal role in LifeMD's ownership structure, collectively holding approximately 44.74% of the company's shares as of July 18, 2025. This significant stake is distributed among 217 institutional owners. Prominent among these are BlackRock, Inc., which held 2,481,761 shares representing 5.8% ownership as of November 2024, and The Vanguard Group Inc. Other substantial institutional shareholders include Royce & Associates Lp, Connor, Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Morgan Stanley, and State Street Corp. The substantial presence of these large investment firms underscores a growing institutional interest in LifeMD's business model and future prospects, aligning with the company's focus on achieving profitability.

Understanding LifeMD's Shareholder Landscape

LifeMD's ownership is a blend of institutional, insider, and public holdings. The increasing influence of institutional investors suggests a maturing company with growing appeal to the broader investment community.

• Institutional investors hold approximately 44.74% of LifeMD shares as of July 2025.
• BlackRock, Inc. and The Vanguard Group Inc. are among the top institutional holders.
• Founders and management collectively own about 25% of the company as of March 2024.
• Justin Schreiber, CEO, holds 2,753,715 shares, representing 6.06% ownership as of June 2025.
• Strategic investments, such as Medifast's $10 million investment in December 2023, also impact ownership.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

LifeMD's governance is steered by a Board of Directors consisting of seven members, a mix of executive and independent directors. This board is instrumental in shaping the company's strategic direction and ensuring robust oversight. As of April 28, 2025, the board includes Justin Schreiber, who serves as both Chairman and Chief Executive Officer, alongside John Strawn, a Partner at Strawn Pickens LLP. The board also features Dr. Joseph V. DiTrolio, M.D., a Clinical Professor of Surgery; Roberto Simon, Chief Financial Officer at Orveon LLC; Dr. Joan LaRovere, M.D., Director of Innovation and Outcomes at Boston Children's Hospital; William Febbo, the former CEO of OptimizeRx Corporation; and Dr. Calum MacRae, M.D., Ph.D., Vice Chair for Scientific Innovation at Brigham and Women's Hospital.

The composition of the board highlights a blend of leadership experience and specialized knowledge. Justin Schreiber, as a co-founder and the key executive, holds a significant stake, reflecting a strong insider presence. The other directors bring valuable expertise from legal, medical, and financial sectors, with several holding independent positions. This diverse background is crucial for navigating the complexities of the healthcare industry. The company's 2024 shareholder letter indicates that Justin Schreiber and Stefan Galluppi, among the largest shareholders, along with the management team and founders, collectively own approximately 25% of the company. This substantial insider ownership fosters a close alignment between the board, senior management, and the broader investor base, reinforcing confidence in LifeMD's leadership and vision.

LifeMD operates under a standard one-share-one-vote equity structure, typical for companies listed on Nasdaq, with no publicly disclosed dual-class share arrangements or special voting rights. While there haven't been recent public reports of significant proxy battles or activist investor campaigns, the substantial ownership by insiders, combined with the increasing participation of institutional investors, creates a balanced control dynamic. The board's structure emphasizes medical acumen and financial prudence, essential attributes for a telehealth provider operating in a rapidly evolving healthcare environment. Understanding the Brief History of LifeMD can provide further context on its ownership evolution.

Understanding LifeMD's Ownership Structure

LifeMD's ownership is characterized by a strong insider presence and a commitment to corporate governance.

• The company follows a one-share-one-vote policy.
• Key executives and founders hold a significant portion of the company's stock.
• The board composition reflects a strategic focus on medical and financial expertise.
• Institutional investors are also playing a growing role in LifeMD's shareholder base.

LifeMD Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past 3-5 years, the company has seen significant financial growth and strategic shifts. In the first quarter of 2025, revenue increased by a substantial 49% year-over-year, reaching $65.7 million. This period also marked a milestone with the company achieving its first-ever quarter of positive GAAP net income, amounting to $0.6 million, or $0.01 per diluted share. Projections for the full year 2025 indicate consolidated revenue between $268 million and $275 million, with an anticipated 200% growth in telehealth adjusted EBITDA to $21 million.

Institutional investors remain a significant presence in the company's ownership landscape. As of July 18, 2025, a total of 217 institutional owners collectively held over 20.3 million shares, representing approximately 44.74% of the company's total shares. This period saw varied activity among these institutions; for example, D. E. Shaw & Co., Inc. increased its holdings by 417,403 shares (+263.5%) in Q1 2025, and Citadel Advisors LLC added 411,865 shares (+561.8%) during the same quarter. Conversely, Divisadero Street Capital Management, LP divested its entire stake of 1,508,403 shares (-100.0%) in Q4 2024. Insider transactions also occurred, with CEO Justin Schreiber selling 25,000 shares for $334,458 in July 2025, and other executives like Marc David Benathen and Stefan Galluppi also participating in share sales.

Strategic acquisitions and partnerships have been central to the company's expansion. In April 2025, the company acquired key assets from Optimal Human Health MD, marking a focused entry into the women's health market, a sector estimated to be worth $60 billion to $70 billion by 2030. Further strengthening its market position, the company partnered with Medifast in December 2023, which included a $10 million equity investment. Additional collaborations include a March 2025 partnership with Eli Lilly to provide access to lower-cost Zepbound and a May 2024 alliance with Withings, Inc. to integrate in-home health monitoring devices for patients managing their weight. These strategic moves underscore a commitment to broadening service offerings and market reach within the telehealth sector, a common strategy that can lead to founder dilution but also enhances market standing and future growth potential. Understanding these Revenue Streams & Business Model of LifeMD provides context for these developments.

Institutional Investor Activity

Institutional investors hold a significant portion of the company's shares, with 217 institutions owning over 44.74% as of July 2025. Recent activity shows both increases and decreases in holdings by major institutions, reflecting dynamic market strategies.

Insider Transactions

Insider selling has been noted, with the CEO and other executives engaging in share sales during 2025. These transactions are part of normal executive compensation and portfolio management practices.

Strategic Acquisitions and Partnerships

The company has actively pursued strategic acquisitions and partnerships to expand its market presence, particularly in women's health. These moves are designed to enhance service offerings and capture new market opportunities.

Financial Performance Highlights

Recent financial reports show strong year-over-year revenue growth and the achievement of positive net income for the first time. Future projections indicate continued revenue expansion and significant growth in adjusted EBITDA.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE